The PARP inhibitor has been specifically recommended for NHS use alongside anti-androgen therapy Zytiga (abiraterone) and prednisone or prednisolone in adults with untreated hormone-relapsed metastatic prostate cancer who cannot have or do not want chemotherapy.
More than 52,000 men are diagnosed with prostate cancer each year in the UK and up to 20% of those with advanced cases will develop castration-resistant prostate cancer (CRPC) within five years…
